Resumen de: EP4461219A2
Methods, computers, and systems used to improve accuracy of analyte level measurement of an in vivo positioned analyte sensor are disclosed herein. The methods, computers, and systems disclosed herein may be used to provide a calibrated analyte level. Specific embodiments relate to methods, computers, and systems for improving accuracy of glucose measurement of an in vivo positioned glucose sensor.
Resumen de: WO2023133231A1
A system and method for personalized calibration for glucose sensing. In some embodiments, the method includes obtaining a plurality of first glucose measurements from a subject, at a plurality of first sampling times during a time interval, using a first glucose sensor; obtaining a plurality of second glucose measurements from the subject, at a plurality of second sampling times during the time interval, using a second glucose sensor; and estimating a first in-vivo calibration parameter for the first glucose sensor and the second glucose sensor, based on the first glucose measurements and the second glucose measurements, wherein a first in-vivo time-constant, relating blood glucose to an output of the first glucose sensor, is different from a second in-vivo timeconstant, relating blood glucose to an output of the second glucose sensor.
Resumen de: US2024366874A1
A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining an insulin-on-board (IOB) value, wherein the IOB value is a quantity of insulin remaining in a patient following delivery of a bolus of insulin, scaling a total daily dose (TDD) value by a factor, to generate a result having a value that is less than the TDD value, based on determining that the IOB value is greater than the result, identifying a condition in which the patient's glucose level will continue to decrease after suspension of basal insulin dosage delivery, and responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
Resumen de: US2024366118A1
This invention provides methods and devices for the non-invasive measurement of select substances in human tissue such as, for example, blood glucose. The non-invasive methods and devices use a light source such as a laser diode for transmitting light energy pulses into human tissue. A piezoelectric component and/or ultrasonic transducer detects vibration of the tissue and generates an acoustic signal that is transmitted to a microcontroller. The concentration of the substance, for example, blood glucose is measured using at least one algorithm. Preferably, the device incorporates embedded machine learning (ML), artificial intelligence (AI), internet of things (IoT), app, and blockchain programming, wherein the programming is designed to encrypt and/or deidentify personal data and measurements.
Resumen de: US2024366122A1
Wireless, lightweight, and multifunctional chemical sensors and methods for detection of biomarkers in bodily fluids are described. Systems and methods are directed to an LC (inductor-capacitor) resonance circuit configured to detect multiple biomarkers in bodily fluids of a subject through frequency modulation. The system may be comprised within a wearable device or within a medical implant, depending on the implementation. The body fluid may comprise sweat, cerebrospinal fluid, blood, saliva, tears, mucus, gastric acid, and/or urine, for example. The biomarkers may comprise Na+, K+, Ca2+, H+, Cl—, glucose, urea, lactate, glutamate, serotonin, cortisol, dopamine, cytokines, and/or epinephrine, for example.
Resumen de: US2024371492A1
Techniques disclosed herein relate generally to diabetes therapy management. In some examples, the techniques involve obtaining therapy-related data (e.g., including sensor glucose data and meal data) of a user of an insulin delivery device for a time period of a plurality of time periods, determining whether the therapy-related data associated with the time period is well-fit data by determining whether a physiological model for the user can be fitted to the therapy-related data associated with the time period, determining one or more parameters of the physiological model by fitting the physiological model to well-fit data associated with the time period, and causing the insulin delivery device to deliver insulin to the user based on the one or more parameters of the physiological model.
Resumen de: WO2024229007A2
Embodiments relate to systems and methods for developing and implementing a model. Developing the model can involve receiving an insulin dosing rule (IDR) including plural metabolic states (Xs) and corresponding insulin dosage recommendations (Us), generating a saturated data set with the plural Xs and corresponding Us so that the saturated data set has optimal data density, generating a saturated look-up table (STL) with the saturated data set, and encoding the STL into a neural network. Implementing the model can involve receiving a measurement indicative of a metabolic state (Xm), implementing a model a SLT encoded into a neural network, the SLT including a saturated data set of optimal data density, wherein implementation of the model applies the Xm to the SLT to identify a corresponding U, and monitoring, analyzing, or influencing a concentration of glucose levels in a fluid using the identified U.
Resumen de: US2024366873A1
A model-based control scheme consisting of either a proportional-integral-derivative (IMC-PID) controller or a model predictive controller (MPC), with an insulin feedback (IFB) scheme personalized based on a priori subject characteristics and comprising a lower order control-relevant model to obtain PID or MPC controller for artificial pancreas (AP) applications.
Resumen de: US2024370162A1
A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Resumen de: EP4458256A2
Electrochemical impedance spectroscopy (EIS) may be used in conjunction with continuous glucose monitoring (CGM) to enable identification of valid and reliable sensor data, as well implementation of Smart Calibration algorithms.
Resumen de: WO2023122929A1
A drug infusion device with integrated power supply comprises a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the pistion forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply; the power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.
Resumen de: WO2023122930A1
Disclosed is a highly integrated drug infusion device, comprising: a drug reservoir 112, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel 114, connected with the screw, driving the screw to push the piston forward by rotation; a power supply 113, used to supply power to the infusion device; and a case, including an upper case 111a and a lower case 111b, for accommodating the drug reservoir 112, the drive wheel 114 and the power supply 113; wherein a three dimensional circuit 136 is provided on the case, and the three dimensional circuit 136 is electrically connected to the power supply 113 to supply power to the infusion device. The three dimensional circuit 136 is arranged on the case and does not occupy the internal space of the infusion device, which can make the internal arrangement of the infusion device more compact and further reduce the volume of the infusion device.
Resumen de: EP4406568A2
A fluid delivery device comprising a fluid reservoir; a transcutaneous access tool fluidly coupled to the fluid reservoir, the transcutaneous access tool including a needle or a trocar; and a transcutaneous access tool insertion mechanism for deploying the transcutaneous access tool, wherein the insertion mechanism is configured to insert and retract the needle/trocar in a single, uninterrupted motion. In certain embodiments, the fluid delivery device may comprise an infusion device comprising a fluid reservoir for containing a therapeutic fluid; and a transcutaneous access tool fluidly coupled to the fluid reservoir for delivering the therapeutic fluid subcutaneously and for introducing a monitoring test strip subcutaneously, and methods of use thereof.
Resumen de: US2024362883A1
Modulation-encoded light, using different spectral bin coded light components, can illuminate a stationary or moving (relative) target object or scene. Response signal processing can use information about the respective different time-varying modulation functions, to decode to recover information about a respective response parameter affected by the target object or scene. Electrical or optical modulation encoding can be used. LED-based spectroscopic analysis of a composition of a target (e.g., SpO2, glucose, etc.) can be performed; such can optionally include decoding of encoded optical modulation functions. Baffles or apertures or optics can be used, such as to constrain light provided by particular LEDs. Coded light illumination can be used with a focal plane array light imager receiving response light for inspecting a moving semiconductor or other target. Encoding can use orthogonal functions, such as an RGB illumination sequence, or a sequence of combinations of spectrally contiguous or non-contiguous colors.
Resumen de: US2024360230A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Resumen de: US2024358920A1
Techniques disclosed herein relate to configurable target glucose values. In some embodiments, the techniques may involve modifying a glucose setpoint from a first target value to a second target value, wherein the second target value is lower than the first target value. The techniques may further involve regulating a glucose level of a patient to the modified glucose setpoint by controlling insulin delivery. The techniques may further involve after a time period has elapsed, reverting the glucose setpoint to the first target value.
Resumen de: US2024358919A1
Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.
Resumen de: US2024358282A1
A device includes a glucose monitor comprising at least one sensor electrode configured to sense signals indicative of interstitial glucose level of a patient. The device also includes a memory and one or more processors implemented in circuitry and in communication with the memory. The one or more processors are configured to cause delivery of a cleaning electrical current to the at least one sensor electrode. The cleaning electrical current is one or more electrochemical cleaning pulses configured to at least partially remove, in vivo and from the sensor electrode, excipients associated with the delivery of a fluid that includes insulin.
Resumen de: US2024358315A1
The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.
Resumen de: US2024358294A1
Embodiments of the invention provide optimized polymeric surfaces adapted for use with implantable medical devices as well as methods for making and using such polymeric surfaces. These polymer surfaces have a constellation of features that function to inhibit or avoid an inflammatory immune response generated by implantable medical devices. Typical embodiments of the invention include an implantable glucose sensor used in the management of diabetes having a polymer surface with the disclosed constellation of features.
Resumen de: US2024358286A1
Provided is a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be accurately measured.
Resumen de: US2024358320A1
Disclosed are a diabetes sensor, a method for manufacturing the diabetes sensor, and a closed-loop control system. The diabetes sensor includes a substrate, a microneedle array arranged on one side of the substrate, and a plurality of electrodes covering the microneedle array and the substrate, wherein the microneedle array includes a plurality of microneedles; and the plurality of electrodes includes an electrochemical sensor and a reverse iontophoresis device; the electrochemical sensor being configured to detect glucose molecules in interstitial fluid and generate an electrical signal; and the reverse iontophoresis device being configured to generate a reverse iontophoresis effect to attract glucose molecules in a deep skin layer to an upper part of dermis where needle tips of the microneedles are located.
Resumen de: US2024358283A1
Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes at least one light source configured to strike a target area of a sample, at least one light detector positioned to receive light from the at least one light source and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, a processor configured to receive the output signal from the at least one light detector based on the received output signal, calculate the attenuance attributable to blood in a sample present in the target area with a ratio factor, eliminate effect of uncertainty caused by temperature dependent detector response of the at least one light detector, and then determine a blood glucose level associated with a sample present in the target area based on the calculated attenuance with the processor.
Resumen de: US2024358285A1
Provided is a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be accurately measured.
Nº publicación: AU2024227267A1 31/10/2024
Solicitante:
DEXCOM INC
Dexcom, Inc
Resumen de: AU2024227267A1
Flexible analyte sensors are provided. Flexible analyte sensors may be flexible continuous analyte sensors that facilitate continuous monitoring of an analyte such as blood glucose. The flexible analyte sensor may have a relatively flexible conductive or non-conductive core, may be formed from a plurality of substantially planar layers, or may be configured to transform from a freestanding sensor ex vivo to a non-freestanding sensor in vivo.